This revealed only five features (from two modalities) that significantly distinguished these patient subgroups (FDR-corrected, q < 0.05): DAT binding in bilateral caudate and putamen and clinical scores on the the Unified PD rating scale, part II (UPDRS-II37). The gene discussed is SLC6A3; the disease is Parkinson disease.